A new study under consideration at BMC Microbiology and published on the Research Square* preprint server describes a potential relationship between antibody titers against the rubella virus and the ...

In Portugal, the recommended age for the second dose of MMR (MMR2) was changed from 10–13 years to 5–6 years for those born in 1994 and afterwards. This study aimed to assess if MMR schedule and time ...

Thirty-nine volunteers, who were either naturally immune to rubella virus or immune as a result of vaccination with RA 27/3, Cendehill, or To-336 vaccines, were challenged intranasally with ...

People with lower levels of antibodies against mumps -- the second "M" in the MMR vaccine -- are likelier to have a severe case of COVID. Vaccines must be rigorously tested before they are deployed en ...

UNIVERSITY PARK, Pa. — When public health officials make policies about when and how vaccination programs are implemented, they must weigh the benefits and risks of how infectious diseases spread ...

Dear Dr. Roach: I am a layman, but I disagree with your recent advice about the MMR vaccination specifically for a person without rubella antibodies. I am 73 years old. When I was 18, I caught rubella ...

When public health officials make policies about when and how vaccination programs are implemented, they must weigh the benefits and risks of how infectious diseases spread throughout the country.

Virion\Serion presents a novel recombinant Rubella spike ectodomain (E1-E2) antigen in comparison with established IVD Rubella IgM assays. The IgM antibodies are detected on magnetic beads coated with ...

Dear Dr. Roach: You recently wrote that "nearly everybody born before 1957 had measles and mumps (but not rubella)." I was born in the early 1950s, so I fall into this category. A few years ago, at my ...

The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early ...

An international team developed a new model, based on a case study of Nigeria, that may help public health officials accelerate the introduction of rubella vaccination in countries that have yet to do ...